TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10599334
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg per day
Study: 10599334
Drug: Thalidomide 300
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 300 mg per day
Study: 6857583
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg four times per day for three days)
Study: 6857583
Drug: Salbutamol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol treatment
Study: 29147795
Drug: Pregabalin 2
Normalized name: pregabalin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 2 mg/kg twice daily
Study: 27401508
Drug: Prophylactic fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic fentanyl pectin nasal spray (FPNS) 15%-25% of total daily opioid dose
Study: 26121347
Drug: Esomeprazole 5
Normalized name: esomeprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks
Study: 12790216
Drug: Morphine 0.4
Normalized name: morphine 0.4 mg/mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.4 mg mL(‐1)
Study: 12790216
Drug: Morphine 0.4
Normalized name: morphine 0.4 mg/mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.4 mg mL(‐1) + MgSO4 30 mg mL(‐1)
Study: 12790216
Drug: Morphine 0.4
Normalized name: morphine 0.4 mg/mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.4 mg mL(‐1) + ketamine 1 mg mL(‐1)
Study: 2062330
Drug: Plasma infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma infusion
Study: 6192139
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage regimen (group A) - MMI: 60 +/- 14.5 mg/day or PTU: 693 +/- 173 mg/day, with T3 addition.
Study: 6192139
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage regimen (group B) - MMI: 13.6 +/- 7 mg/day or PTU: 180 +/- 58 mg/day, without T3 addition.
Study: 24075228
Drug: Cultured allogeneic
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured allogeneic fibroblasts in a crystalloid suspension solution with 2% albumin
Study: 24075228
Drug: Suspension solution
Normalized name: Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension solution alone
Study: 24075228
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (fibroblasts and suspension solution)
Study: 2971565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bronchodilators
Study: 23403474
Drug: Oral citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral citicoline 500 mg twice a day
Study: 22122817
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg and HCT 25 mg
Study: 22122817
Drug: HCT 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCT 25 mg
Study: 19593887
Drug: Intraarticular +
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular + subacromial injection
Study: 19593887
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection
Study: 17047178
Drug: Nutrison Pack
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrison Pack (1-L enteral feeding system)
Study: 17047178
Drug: Glass bottle
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass bottle system (0.5-L)
Study: 12923727
Drug: Angiotensin antagonists,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin antagonists, lifestyle changes, and appropriate drugs to reduce cardiovascular risk factors
Study: 12923727
Drug: Immunosuppressive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapies (corticosteroids, cyclosporine, mycophenolate, cyclophosphamide)
Study: 10839912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epidural morphine and intravenous ketamine
Study: 3730737
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific therapy (control)
Study: 30866027
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling and medical therapy (treated)
Study: 29678193
Drug: Prolonged grief-specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged grief-specific integrative cognitive behavioral therapy (PG-CBT)
Study: 24956865
Drug: Pingshen decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pingshen decoction 1 dose/d, bid po for 8 weeks
Study: 24956865
Drug: NephritisShu tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NephritisShu tablet, 6 tablets, tid po for 8 weeks
Study: 23356030
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose rifampicin (SDR) chemoprophylaxis
Study: 19011427
Drug: Olanzapine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (20 mg/d)
Study: 19011427
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg/d, increasing to 30 mg/d as needed)
Study: 19011427
Drug: Control (Lorazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Lorazepam as needed, total dose ≤ 4 mg/d)
Study: 16151977
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (0.3 U/kg)
Study: 16151977
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (0.3 U/kg)
Study: 16151977
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (0.3 U/kg)
Study: 10999651
Drug: Salbutamol 8
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 8 mg [β‐2]
Study: 10999651
Drug: Pindolol 10
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 10 mg [mainly β‐2]
Study: 10999651
Drug: Xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 200 mg [β‐1]
Study: 8136625
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (1 unit/ml) added to pre-mixed fluids
Study: 26906014
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg before surgery, 40 mg morning of surgery, 40 mg daily after surgery)
Study: 26906014
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg morning of surgery, 40 mg morning after)
Study: 26502545
Drug: Red-hot needle
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Red-hot needle therapy, treated with cauterized needles on specific acupuncture points, once every other day for 30 days.
Study: 26502545
Drug: Routine acupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture, treated with filiform needles on specific acupuncture points, once daily for 30 days.
Study: 23885607
Drug: Motilium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motilium (10 mg orally, three times a day for 2 weeks)
Study: 18455211
Drug: PPAR agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR agonists
Study: 707973
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combination type oral contraceptive
Study: 31537812
Drug: Chemotherapy (n=82)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (n=82)
Study: 31537812
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (n=76)
Study: 23497336
Drug: Eltrombopag 100
Normalized name: eltrombopag 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 100 mg daily
Study: 23648244
Drug: Domestic live
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic live attenuated hepatitis A vaccine (Group A)
Study: 23648244
Drug: Domestic inactivated
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic inactivated hepatitis A vaccine (Group B)
Study: 23648244
Drug: Imported inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported inactivated hepatitis A vaccine (Group C)
Study: 23648244
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Group D)
Study: 21645836
Drug: Tinzaparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (100 IU/kg subcutaneously daily for 90 days) along with usual postoperative care
Study: 21645836
Drug: Usual postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual postoperative care including chemotherapy when indicated
Study: 17089021
Drug: SPS (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPS (600 mg daily)
Study: 9207819
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg once daily
Study: 7820217
Drug: Insulin bolus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin bolus 0.15-0.75 U/kg
Study: 7820217
Drug: Insulin withdrawal
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin withdrawal and 3 days of intensive insulin therapy
Study: 3124602
Drug: Stepwise increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise increase in daily dosage (1 to 4 g/kg) at a steady rate over 24 hours
Study: 3124602
Drug: Stepwise increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise increase in daily dosage (1 to 4 g/kg) at a steady rate over 16 hours, followed by a rest period of eight hours
Study: 3124602
Drug: Full dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dosage (4 g/kg) at a steady rate over 24 hours
Study: 30956160
Drug: Single-implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant overdentures (IODs)
Study: 27739230
Drug: ARC-520 Injection
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARC-520 Injection (0.01-4.0 mg/kg)
Study: 26220024
Drug: Non-drug-using healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug-using healthy males
Study: 22903391
Drug: Lurasidone 40
Normalized name: lurasidone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40 mg
Study: 22903391
Drug: Lurasidone 120
Normalized name: lurasidone 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 120 mg
Study: 21764706
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 µg daily subcutaneous injection for 7 days)
Study: 18385744
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg day(‐1))
Study: 18385744
Drug: Hypertensive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive patients (without treatment)
Study: 11073734
Drug: 4% tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% tea tree oil nasal ointment and 5% tea tree oil body wash
Study: 11073734
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin nasal ointment and triclosan body wash
Study: 8762212
Drug: Combined slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined slow-release verapamil (180 mg daily) and trandolapril (1.6 mg daily)
Study: 8762212
Drug: Atenolol (71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (71 mg daily) and chlortalidone (18 mg daily)
Study: 1315294
Drug: Six additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six additional cycles of chemotherapy (lomustine, cyclophosphamide, doxorubicin, etoposide)
Study: 1315294
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment until relapse (control group)
Study: 27452639
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement of n-3 PUFA (720mg 20:5n3 + 480mg 22:6n3/d)
Study: 15871441
Drug: Albuterol 180
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 180 microg QID via pMDI
Study: 8334946
Drug: Cyclophosphamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (500 mg/m2 initially, increased by 250 mg/m2 to a maximum of 1,000 mg/m2, administered in cycles every 4 weeks)
Study: 8334946
Drug: Cyclophosphamide (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (overall treatment)
Study: 31818839
Drug: Self-regulation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-regulation intervention including daily weighing, tracking weight using an app, planning daily actions for weight loss, and weekly reflection on action plans.
Study: 31818839
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing without further support (control group).
Study: 31818839
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing (control group).
Study: 23892493
Drug: Cumulative Comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative Comfort (CC) for DT1
Study: 23892493
Drug: Cumulative Comfort
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative Comfort (CC) for asymptomatic group
Study: 15243483
Drug: Wand Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wand Plus injection system
Study: 11692587
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg orally daily starting on postoperative day 1 for 14 days)
Study: 9130032
Drug: Methylprednisolone (METH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (METH, 125 mg i.v. infusion followed by 40 mg/d orally for 4 days)
Study: 9130032
Drug: Methylprednisolone (METH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (METH, 40 mg/d orally for 4 days)
Study: 3310197
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg) administered by intravenous injection
Study: 3310197
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by intravenous injection
Study: 20810853
Drug: Single‐fraction radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐fraction radiation therapy of 700 cGy immediately postoperatively (within seventy‐two hours)
Study: 20810853
Drug: Single‐fraction radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐fraction radiation therapy
Study: 9072308
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dolasetron
Study: 9072308
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron
Study: 8257492
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg rhRlx intravenous (iv)
Study: 8257492
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg rhRlx intracervical
Study: 8257492
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg rhRlx intravaginal
Study: 8257492
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg rhRlx (placebo) intravaginal
Study: 8257492
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg rhRlx intravaginal
Study: 8257492
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg rhRlx intravaginal
Study: 29313746
Drug: Resveratrol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (600 mg daily)
Study: 24122760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy without bevacizumab)
Study: 22514150
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin 80 mg/day × 2 days before and 40 mg/day × 30 days after PCI
Study: 22514150
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin treatment
Study: 18403272
Drug: High-dose cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cannabis (7%)
Study: 18403272
Drug: Low-dose cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cannabis (3.5%)
Study: 14620385
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote (45, 90, 135, 180, and 225 mg)
Study: 14620385
Drug: Wood creosote
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood creosote (up to 225 mg)
Study: 8890679
Drug: Fluoxetine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (all doses combined)
Study: 6367325
Drug: Subcutaneous dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dihydroergotamine
Study: 30201053
Drug: Improved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved treatment as usual (iTAU)
Study: 23212185
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patches (TFPs) 25 μg, two patches placed 12 h before surgery
Study: 23212185
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches of identical size
Study: 22851577
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion after exercise
Study: 22851577
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion after exercise
Study: 11879715
Drug: Simvastatin 20-mg
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20-mg per day
Study: 7575120
Drug: Isolated limb
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated limb perfusion with high flow rate (869 +/- 122 mL/min)
Study: 7575120
Drug: Isolated limb
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated limb perfusion with low flow rate (286 +/- 62 mL/min)
Study: 26575524
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg twice per day (BID)
Study: 22487032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two delta rule learning processes
Study: 19279300
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (50 g total and 25 g soluble fiber)
Study: 19279300
Drug: Moderate-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-fiber diet (24 g total and 8 g soluble fiber)
Study: 17250692
Drug: Omalizumab (anti-IgE)
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab (anti-IgE) therapy
Study: 7521090
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg DOX once in the AM
Study: 7521090
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg DOX once in the PM
Study: 7521090
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg DOX once in the AM
Study: 7521090
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg DOX once in the PM
Study: 2683019
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g taken 1/2 h before breakfast and at bedtime)
Study: 29664896
Drug: Prazosin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (16 mg daily for 6 weeks)
Study: 29664896
Drug: Prazosin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (in optimal treatment exposure subgroup)
Study: 21051493
Drug: Remifentanil concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentrations (CeREMI) at 2, 4, or 6 ng m⁻¹ with propofol fixed at 3 µg ml⁻¹
Study: 9627304
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) therapy
Study: 8157550
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg po
Study: 31051498
Drug: AA-60 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-60 (8 AAs, 60 mmol/L Na+)
Study: 31051498
Drug: AA-30 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-30 (5 AAs, 30 mmol/L Na+)
Study: 26148930
Drug: MPC injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPC injections (150 million cells)
Study: 26148930
Drug: MPC injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPC injections (25 million cells)
Study: 26148930
Drug: MPC injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPC injections (75 million cells)
Study: 10664917
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg bid)